Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why updated TRUST-I and TRUST-II results make IBTROZI a top contender in targeted lung cancer therapy
Nuvation Bio unveils pivotal TRUST-I and TRUST-II updates for IBTROZI in ROS1+ lung cancer, showing strong durability and brain response. Read more now.
AstraZeneca’s Tagrisso redefines survival bar in advanced EGFR-mutant NSCLC
AstraZeneca’s Tagrisso combo extends survival to nearly 4 years in advanced EGFR-mutated lung cancer. Find out what this means for treatment norms.
Can ifinatamab deruxtecan redefine treatment for late-stage small cell lung cancer? Here’s what the trial showsÂ
Discover how ifinatamab deruxtecan delivered a 48% objective response rate in pretreated ES-SCLC. Read on for trial results and next steps.
Vonvendi gets green light for pediatric bleeding disorder care in FDA expansion
Find out how the FDA's expanded approval of Vonvendi opens new treatment avenues for children and adults with all types of von Willebrand disease.
GLP-1 crackdown intensifies: What FDA’s new green list means for tirzepatide safety
The FDA’s new GLP-1 green list aims to block illegal semaglutide and tirzepatide imports. Find out how it could reshape the compounding pharmacy landscape.
Why CVS Caremark’s decision to drop Zepbound could reshape the billion-dollar weight-loss drug war
CVS Caremark faces a lawsuit after dropping Eli Lilly’s Zepbound from coverage. Explore patient, investor, and payer implications in the GLP-1 market battle.
Why did Newron Pharmaceuticals stock rise by nearly 8% and what triggered investor enthusiasm?
Newron Pharmaceuticals stock rallies 7.88% after evenamide schizophrenia trial data and WCBP presentations highlight breakthrough potential. Read what’s next for investors.
BioNTech stock jumps 8.66% after DB-1303 meets primary endpoint in breast cancer trial
BioNTech stock surged after DB-1303 met its Phase 3 endpoint in HER2-positive breast cancer. Find out what this means for global oncology strategy.
Sarepta Therapeutics awards 25 Route 79 scholarships in 2025–2026, but what makes this Duchenne program unique?
Sarepta Therapeutics awarded 25 Route 79 scholarships for 2025–2026 to support students impacted by Duchenne. See how this initiative strengthens community ties.
What makes Aptar Pharma’s latest nasal drug delivery bet a potential market disruptor?
Aptar Pharma teams up with Dianosic to advance a bioresorbable nasal scaffold platform for chronic sinus and rhinitis care. Find out how this could reshape treatment.